Denys-Drash Syndrome (DDS) Overview
Learn About Denys-Drash Syndrome (DDS)
Denys-Drash syndrome is a condition that affects the kidneys and genitalia.
Mutations in the WT1 gene cause Denys-Drash syndrome. The WT1 gene provides instructions for making a protein that regulates the activity of other genes by attaching (binding) to specific regions of DNA. On the basis of this action, the WT1 protein is called a transcription factor. The WT1 protein plays a role in the development of the kidneys and gonads (ovaries in females and testes in males) before birth.
The prevalence of Denys-Drash syndrome is unknown; at least 150 affected individuals have been reported in the scientific literature.
This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.
University Of Arkansas For Medical Sciences
Nithin Karakala is a Nephrologist in Little Rock, Arkansas. Dr. Karakala and is rated as an Advanced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). His top areas of expertise are End-Stage Renal Disease (ESRD), Nephrosclerosis, Renovascular Hypertension, and Chronic Kidney Disease. Dr. Karakala is currently accepting new patients.
University Of Arkansas For Medical Sciences
David Becton is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Little Rock, Arkansas. Dr. Becton has been practicing medicine for over 46 years and is rated as an Advanced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). His top areas of expertise are Hepatoblastoma, Ependymoma, Shwachman-Diamond Syndrome, Ataxia-Pancytopenia Syndrome, and Bone Marrow Aspiration. Dr. Becton is currently accepting new patients.
University Of Arkansas For Medical Sciences
Manisha Singh is a Nephrologist in Little Rock, Arkansas. Dr. Singh and is rated as an Experienced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). Her top areas of expertise are End-Stage Renal Disease (ESRD), Acute Kidney Failure, Chronic Kidney Disease, and Renovascular Hypertension. Dr. Singh is currently accepting new patients.
Summary: This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide...
Summary: This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a...
Published Date: March 01, 2013
Published By: National Institutes of Health